EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparison of outcomes following subcutaneous or intravenous alemtuzumab administered prior to reduced intensity conditioning for transplantation in pediatric sickle cell disease

Alexandra Plavsa, Tara Suresh, Stuti Dalal, Lucia Mirea, Roberta H Adams, Shalini Shenoy, Alexander Ngwube

Transplant Immunology · 2025

DOI: 10.1016/j.trim.2025.102179 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Transplant Immunology, 2025. Verfasst von Alexandra Plavsa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Creighton University School of Medicine, Phoenix, AZ, USA. Hauptthemen laut MEDLINE: Alemtuzumab, Anemia, Sickle Cell, Hematopoietic Stem Cell Transplantation, Transplantation Conditioning. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Creighton University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Alemtuzumab-containing conditioning regimens are used for allogeneic hematopoietic stem cell transplantation (HSCT) to reduce acute and chronic graft-versus-host disease (GVHD) and the risk of graft rejection. Alemtuzumab is typically administered intravenously but is often accompanied by infusion-related side effects, including injection site reactions and anaphylaxis. Little is known about the routes of administration and if they differ in safety and efficacy in pediatric patients, especially when used in transplant conditioning. OBJECTIVES: To compare adverse effects and efficacy outcomes between intravenous and subcutaneous alemtuzumab administration in pediatric patients with sickle cell disease who have undergone HSCT. STUDY DESIGN: A retrospective cohort of 49 pediatric patients with sickle cell disease aged 4-16 years underwent HSCT and received either intravenous or subcutaneous alemtuzumab at St. Louis Children's Hospital or Phoenix Children's Hospital. The incidence of infusion-related reactions, neutrophil and platelet recovery, graft failure, and immune reconstitution were compared. RESULTS: We found that subcutaneous alemtuzumab administration elicited fewer infusion-related reactions than intravenously administered drug (p = 0.038). No significant differences in engraftment rates, graft failure rates, infectious complications, acute GVHD, and immune reconstitution were found between the two groups. CONCLUSION: Subcutaneous administration of alemtuzumab for children undergoing transplant for sickle cell disease is safe and effective.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlemtuzumabAnemia, Sickle CellHematopoietic Stem Cell TransplantationTransplantation ConditioningGraft vs Host DiseaseGraft RejectionHumansChildAdolescentFemaleMaleChild, PreschoolRetrospective StudiesInjections, SubcutaneousAdministration, IntravenousTreatment OutcomeTransplantation, Homologous

Stichwörter der Autor:innen

AlemtuzumabHSCTPediatricSickle cell disease

Substanzen

Alemtuzumab

Autor:innen und Institutionen

  • Department of Pediatrics, Creighton University School of Medicine, Phoenix, AZ, USA.
  • Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, United States of America.
  • Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ, USA.
  • Department of Pediatrics, Creighton University School of Medicine, Phoenix, AZ, USA; Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ, USA. Electronic address: axngwube@texaschildrens.org.

Förderung

  • Creighton University

Zitieren

APA

Plavsa, A., Suresh, T., Dalal, S., Mirea, L., Adams, R. H., Shenoy, S., & Ngwube, A. (2025). Comparison of outcomes following subcutaneous or intravenous alemtuzumab administered prior to reduced intensity conditioning for transplantation in pediatric sickle cell disease. Transplant Immunology. https://doi.org/10.1016/j.trim.2025.102179

Vancouver

Plavsa A, Suresh T, Dalal S, Mirea L, Adams RH, Shenoy S, et al. Comparison of outcomes following subcutaneous or intravenous alemtuzumab administered prior to reduced intensity conditioning for transplantation in pediatric sickle cell disease. Transplant Immunology. 2025. doi:10.1016/j.trim.2025.102179

BibTeX
@article{Plavsa2025,
  author = {Plavsa, Alexandra and Suresh, Tara and Dalal, Stuti and Mirea, Lucia and Adams, Roberta H and Shenoy, Shalini and Ngwube, Alexander},
  title = {Comparison of outcomes following subcutaneous or intravenous alemtuzumab administered prior to reduced intensity conditioning for transplantation in pediatric sickle cell disease},
  journal = {Transplant Immunology},
  year = {2025},
  doi = {10.1016/j.trim.2025.102179}
}
Kostenlos starten →